PRA Health Sciences (PRA) experts have significant experience providing end-to-end risk management services. Our integrated global teams identify innovative solutions to satisfy key regulatory requirements and provide effective strategies to ensure the benefit-risk profile of the product remains favorable for patients.
PRA Health Sciences To Report Fourth Quarter 2014 Earnings
PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its fourth quarter and year end 2014 results after the market closes on Wednesday, February 18,…
Optimize drug therapy with respect to the patient’s genotype, ensuring maximum drug efficiency with minimal adverse effects.
Pharmacogenomics (PGx) Fact Sheet
Pharmacogenomics aims to develop rational means to optimize drug therapy with respect to the patient’s genotype, ensuring maximum drug efficiency…